Home > Ozempic GLP-1 Lawsuit > Gastroparesis Cases
Were You (or a Loved One) Diagnosed with Gastroparesis, Stomach Paralysis or Delayed Gastric Emptying After Taking Ozempic, Mounjaro, Wegovy, Rybelsus, Trulicity or Other GLP-1 Medication?
GLP-1 Gastroparesis Lawsuits & Settlements
Reviewed by Jacobs Kolton, Chtd. Attorneys at Law; Updated June 2026
The Ozempic and GLP-1 gastroparesis lawsuits involve claims that manufacturers of GLP-1 medications such as Ozempic, Wegovy, Mounjaro, Rybelsus, Trulicity, Zepbound, and Saxenda failed to adequately warn patients and doctors about the potential risk of developing gastroparesis (i.e., stomach paralysis or delayed gastric emptying), a serious gastrointestinal injury that can cause persistent nausea, vomiting, abdominal pain, bloating, dehydration, malnutrition, hospitalization, or the need for feeding tubes or other invasive treatment.
Our team of drug injury attorneys and class action lawyers is investigating potential GLP-1 gastroparesis lawsuit cases and settlement claims of individuals who were diagnosed with stomach paralysis or gastroparesis after using Ozempic, Mounjaro, Wegovy, Rybelsus, Trulicity, Zepbound, Saxenda or other GLP-1 agonist medications.
If you or a loved one were diagnosed with gastroparesis (stomach paralysis) after taking Ozempic, Mounjaro, Wegovy or Rybelsus, you may be entitled to recover compensation from a gastroparesis lawsuit case or settlement claim.
Gastroparesis (also known as stomach paralysis) is a chronic disease that affects the nerves and muscles in the stomach, interfering with the muscle activity (peristalsis), making stomach muscle contractions slower and weaker, slowing the movement of food through the stomach and small intestine and causing food not to be properly processed or emptied. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), gastroparesis is relatively rare: out of 100,000 people, about 10 men and 40 women are diagnosed with gastroparesis.
Unfortunately, a study published in JAMA, found that the use of certain diabetes or weight loss medications (i.e., GLP-1 agonists such as Ozempic, Mounjaro, Wegovy, or Rybelsus) may be associated with an increased risk of developing stomach paralysis or gastroparesis.
Patients diagnosed with gastroparesis are now coming forward and filing Ozempic GLP-1 gastroparesis injury lawsuits seeking compensation and justice for the harm and suffering they may have endured.
Ozempic Gastroparesis Lawsuits: Overview
- What Is The Ozempic Gastroparesis Lawsuit About?
- What Is Gastroparesis (Stomach Paralysis)?
- What Are GLP-1 Agonist Medications (e.g., Ozempic, Mounjaro)?
- Who May Be Eligible For a Gastroparesis Lawsuit or Settlement?
- Can Ozempic, Mounjaro or Wegovy Cause Gastroparesis?
- What Are Possible Signs or Symptoms of Gastroparesis?
- What Are Potential Complications Of Gastroparesis?
- Are There Medical Treatments For Gastroparesis?
- Can I Recover Compensation From a Gastroparesis Lawsuit?
- Can Families Recover From Gastroparesis Wrongful Death Cases?
- Is There A Deadline To File an Ozempic Gastroparesis Lawsuit?
- Request A Free Case Review From A Gastroparesis Injury Lawyer
Gastroparesis Lawsuit & Settlement Cases
Gastroparesis lawsuit and settlement cases potentially being investigated include claims of individuals who, after taking the diabetes and/or weight loss medications Ozempic, Mounjaro, Wegovy or Rybelsus, were diagnosed with, and received medical treatment and/or were hospitalized for, gastroparesis, stomach paralysis and other gastrointestinal problems, including the following:
- Gastroparesis
- Stomach paralysis
- Gastric paralysis
- Abdominal paralysis
- Digestive tract paralysis
- Frozen stomach
- Delayed gastric emptying
- Slow stomach emptying
- Gastric palsy
- Gastric stasis
- Gastric atony
- Gastrointestinal autonomic neuropathy
- Gastropathy
- Gastroenteritis
- Severe functional dyspepsia
- Other gastrointestinal injury lawsuit cases
If you or someone you love took Ozempic, Mounjaro, Wegovy, Rybelsus, or other GLP-1 medications and were later diagnosed with gastroparesis, stomach paralysis or GI issues, you may qualify to recover money from an Ozempic gastroparesis lawsuit or settlement case.
Studies Linking Ozempic/GLP-1 to Gastroparesis
Several studies have found a potential link between GLP-1 medications and risk of developing gastroparesis, including:
| Medical Study or Warning | Summary |
|---|---|
| JAMA, Sodhi et al., “Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss,” 2023 | This claims-database cohort study found that GLP-1 agonists used for weight loss were associated with higher risks of serious gastrointestinal events compared with bupropion-naltrexone, including gastroparesis with an adjusted hazard ratio of 3.67 and bowel obstruction with an adjusted hazard ratio of 4.22. The authors noted that these events were rare but potentially serious. |
| BMJ Open Gastroenterology, Aneke-Nash et al., “Comparing the risk of gastroparesis following different modalities for treating obesity,” 2025 | This study investigated the risk of gastroparesis (stomach paralysis) among over 55,000 individuals with obesity but without type 2 diabetes, comparing those treated with semaglutide, bupropion-naltrexone, or sleeve gastrectomy. Using large US claims-based datasets from 2018 to 2022, researchers found that patients using semaglutide had a significantly higher incidence of gastroparesis (6.5 per 1000 person-years) than those treated with bupropion-naltrexone (2.1 per 1000) or sleeve gastrectomy (1.1 per 1000). After adjusting for baseline characteristics, semaglutide users were more than three times as likely to develop the condition compared to the medication group and over six times as likely compared to the surgery group. |
| American Society of Anesthesiologists Consensus Guidance, 2023 | ASA warned that GLP-1 receptor agonists are associated with nausea, vomiting and delayed gastric emptying, which may increase the risk of regurgitation and aspiration during anesthesia or deep sedation. |
| JAMA Surgery, Sen et al., “GLP-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia,” 2024 | This study evaluated residual gastric content before anesthesia and found that GLP-1 receptor agonist use was associated with increased residual gastric content, a clinical marker relevant to delayed stomach emptying and aspiration risk. |
| Digestive Disease Week 2024 / Cleveland Clinic, “Gastroparesis Risk in Patients with Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” 2024 | This DDW 2024 study, summarized by Cleveland Clinic, evaluated adults with type 2 diabetes who were prescribed GLP-1 receptor agonists, including dulaglutide, semaglutide, liraglutide, lixisenatide, exenatide, tirzepatide, and albiglutide. Using the TriNetX multi-institutional database, researchers found an association between GLP-1 receptor agonist use and increased risk of a new gastroparesis diagnosis at 6, 9, 12, 18, and 24 months. The study is relevant to GLP-1 gastroparesis claims because it used real-world patient data and focused directly on new-onset gastroparesis after GLP-1 exposure. |
Gastroparesis Signs & Symptoms
Gastroparesis signs and symptoms can potentially include:
- Food sitting in stomach for a long time
- Delayed gastric emptying
- Slow stomach emptying
- Excessive vomiting
- Excessive nausea
- Excessive bloating
- Too much belching
- Stomach pain
- Stomach ache
- Spasms of the stomach wall
- Feel nauseous like have to throw up
- Feeling full immediately after eating (early satiety)
- Feeling full for a long time after eating
- Regurgitating food
- Indigestion
- Acid reflux or heartburn
- Changes in blood sugar levels
- Lack of appetite
- Weight loss
- Malnutrition
- Constipation
- Delayed bowel movements
- Undigested pieces of food in stool
- Distended (stretched) stomach
- Dehydration
- Blood sugar fluctuations
- Bacteria growth
- Infections
- Body aches (myalgia)
- Muscle weakness
- Other gastroparesis symptoms
Procedures and tests used by gastroenterologists or internists to diagnose gastroparesis can include gastric emptying tests (e.g., a gastric emptying scintigraphy (GES) test that detects the movement of radioactive material to monitor the rate at which food leaves the stomach, a gastric motility breath test (GEBT) that can show how fast the stomach empties after consuming food, a SmartPill wireless motility capsule, etc.), an upper gastrointestinal (GI) endoscopy (to visually examine the upper digestive system, including the stomach), an abdominal ultrasound, upper GI series x-ray, MRI, and CT Scan.
Gastroparesis (Stomach Paralysis) Complications
Complications from gastroparesis can potentially include:
- Severe protein-calorie malnourishment
- Bezoars (mass of indigestible material in stomach)
- Mallory Weiss tears from retching and vomiting
- Blood sugar complications
- Surgical procedure-related complications
- Narcotic dependence and social stigma
- Recurrent hospitalizations
- Significant healthcare costs
- Lower quality of life
- Other gastroparesis complications
Gastroparesis Treatments
There is presently no cure for gastroparesis. Some treatments exist to treat symptoms and side effects. Gastroparesis treatments can include: medications to stimulate stomach muscles and nerves to allow stomach to empty, medications to control vomiting or nausea, medications to relieve pain, medications to treat heartburn, medications to manage blood sugar, gastric bypass surgery (including a partial gastrectomy to remove or close off part of the stomach and gastrojejunostomy to place a feeding tube in the small intestine (jejunostomy tube) to connect the stomach to the middle part of the small intestine (jejunum) while bypassing the first part (duodenum), surgery to place a gastric venting tube to relieve pressure, a pyloroplasty (to relax and expand the muscular valve (pylorus) at the bottom of the stomach that empties food out of it), a gastric peroral endoscopic myotomy (G-POEM), nutritional/diet therapy to make sure the body has sufficient nutrition and is hydrated, among other treatments.
If you or a loved one were diagnosed with gastroparesis (stomach paralysis) after taking Ozempic, Mounjaro, Wegovy, or Rybelsus, you may be entitled to recover compensation from a gastroparesis stomach paralysis lawsuit case or settlement claim. Contact a drug injury lawyer to request a free case review.
*If you or a loved one are experiencing health issues, side effects or complications after taking a prescription drug or medication, we urge you to promptly consult with your doctor or physician for an evaluation.
**The listing of a company (e.g., Novo Nordisk, Eli Lilly) or product (e.g., Ozempic, Mounjaro, Wegovy, Rybelsus, Trulicity, Saxenda or Zepbound) is not meant to state or imply that the company acted illegally or improperly or that the product is unsafe or defective; rather only that an investigation may be, is or was being conducted to determine whether legal rights have been violated.
***The use of any trademarks, tradenames or service marks is solely for product identification and/or informational purposes.
Fill out the form to request a free attorney review.